| Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes SA Long, J Thorpe, HA DeBerg, V Gersuk, JA Eddy, KM Harris, M Ehlers, ... Science Immunology 1 (5), eaai7793, 2016 | 211 | 2016 |
| Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation … A Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, GC Hildebrandt, ... The Lancet Oncology 23 (8), 1066-1077, 2022 | 123 | 2022 |
| Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, J Arnason, ... Blood, The Journal of the American Society of Hematology 139 (12), 1794-1806, 2022 | 100 | 2022 |
| Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes SA Long, J Thorpe, KC Herold, M Ehlers, S Sanda, N Lim, PS Linsley, ... Cellular immunology 319, 3-9, 2017 | 86 | 2017 |
| Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia … WG Wierda, KA Dorritie, J Munoz, DM Stephens, SR Solomon, ... Blood 136, 39-40, 2020 | 66 | 2020 |
| A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium … LK McNeil, L Price, CM Britten, M Jaimes, H Maecker, K Odunsi, ... Cytometry Part A 83 (8), 728-738, 2013 | 66 | 2013 |
| Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype JD Lord, SA Long, DM Shows, J Thorpe, K Schwedhelm, J Chen, M Kita, ... Clinical Immunology 193, 24-32, 2018 | 35 | 2018 |
| Results from the first phase 1 clinical study of the B-cell maturation antigen (BCMA) Nex T chimeric antigen receptor (CAR) T cell therapy CC-98633/BMS-986354 in patients (pts … LJ Costa, SK Kumar, S Atrash, M Liedtke, G Kaur, BA Derman, ... Blood 140 (Supplement 1), 1360-1362, 2022 | 31 | 2022 |
| Immunology of Diabetes Society T‐Cell Workshop: HLA class II tetramer‐directed epitope validation initiative EA James, R Mallone, NC Schloot, MC Gagnerault, J Thorpe, ... Diabetes/Metabolism Research and Reviews 27 (8), 727-736, 2011 | 28 | 2011 |
| Rapid MRD-negative responses in patients with relapsed/refractory CLL treated with Liso-Cel, a CD19-directed CAR T-cell product: preliminary results from transcend CLL 004, a … T Siddiqi, JD Soumerai, WG Wierda, JA Dubovsky, HH Gillenwater, ... Blood 132, 300, 2018 | 27 | 2018 |
| Efficient CRISPR/Cas9 disruption of autoimmune-associated genes reveals key signaling programs in primary human T cells W Anderson, J Thorpe, SA Long, DJ Rawlings The Journal of Immunology 203 (12), 3166-3178, 2019 | 22 | 2019 |
| Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative R Mallone, M Scotto, CN Janicki, EA James, L Fitzgerald‐Miller, ... Diabetes/Metabolism Research and Reviews 27 (8), 720-726, 2011 | 22 | 2011 |
| TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts … T Siddiqi, KA Dorritie, JD Soumerai, DM Stephens, JA Dubovsky, ... Journal of Clinical Oncology 37 (15_suppl), 7501-7501, 2019 | 20 | 2019 |
| Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state K Schwedhelm, J Thorpe, SA Murray, M Gavin, C Speake, C Greenbaum, ... Clinical Immunology 181, 67-74, 2017 | 13 | 2017 |
| Avidity-dependent programming of autoreactive T cells in T1D I Durinovic-Belló, VH Gersuk, C Ni, R Wu, J Thorpe, N Jospe, S Sanda, ... PloS one 9 (5), e98074, 2014 | 13 | 2014 |
| Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol 1 (5): eaai7793 SA Long, J Thorpe, HA DeBerg, V Gersuk, J Eddy, KM Harris, M Ehlers, ... | 12 | 2016 |
| Lisocabtagene maraleucel as second-line therapy for R/R large b-cell lymphoma in patients not intended for hematopoietic stem cell transplant: Final analysis of the phase 2 … AR Sehgal, D Hoda, PA Riedell, N Ghosh, M Hamadani, G Hildebrandt, ... Blood 142, 105, 2023 | 11 | 2023 |
| Lisocabtagene maraleucel (liso-cel) for treatment of second-line (2L) transplant noneligible (TNE) relapsed/refractory (R/R) aggressive large B-cell non-Hodgkin lymphoma (NHL … AR Sehgal, G Hildebrandt, N Ghosh, JE Godwin, ND Wagner-Johnston, ... Journal of Clinical Oncology 38 (15_suppl), 8040-8040, 2020 | 9 | 2020 |
| Exploration of tumor biopsy gene signatures to understand the role of the tumor microenvironment in outcomes to lisocabtagene maraleucel NE Olson, SP Ragan, DJ Reiss, J Thorpe, Y Kim, JS Abramson, C McCoy, ... Molecular Cancer Therapeutics 22 (3), 406-418, 2023 | 6 | 2023 |
| Lisocabtagene maraleucel (liso-cel) for treatment of second-line transplant noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): initial Results … AR Sehgal, J Godwin, J Pribble, L Wang, J Thorpe, GC Hildebrandt Blood 134, 2882, 2019 | 6 | 2019 |
